345 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
VRTX Vertex Pharmaceuticals Incorporated $175.8 $44.93B N/A
Article Searches
Spero Posts Preliminary Data on SPR720 for Pulmonary Disease http://www.zacks.com/stock/news/656485/spero-posts-preliminary-data-on-spr720-for-pulmonary-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-656485 Dec 05, 2019 - Spero (SPRO) reports preliminary findings from a phase I first-in-human study on SPR720, presently being evaluated for the treatment of nontuberculous mycobacterial pulmonary disease.
Gene Therapy the Next Best Thing: Here's Why (Revised) http://www.zacks.com/stock/news/655272/gene-therapy-the-next-best-thing-heres-why-revised?cid=CS-ZC-FT-analyst_blog|investment_ideas-655272 Dec 05, 2019 - Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Gene Therapy the Next Best Thing: Here's Why http://www.zacks.com/stock/news/654120/gene-therapy-the-next-best-thing-heres-why?cid=CS-ZC-FT-analyst_blog|investment_ideas-654120 Dec 04, 2019 - Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
Here's Why Vertex Pharmaceuticals Rose 13.4% in November https://www.fool.com/investing/2019/12/04/heres-why-vertex-pharmaceuticals-rose-134-in-novem.aspx?source=iedfolrf0000001 Dec 04, 2019 - The rare-disease specialist is putting together a respectable end-of-year run.
Seattle Genetics, Astellas Tie Up With Merck for Cancer Study http://www.zacks.com/stock/news/652595/seattle-genetics-astellas-tie-up-with-merck-for-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-652595 Dec 03, 2019 - Seattle Genetics (SGEN) and Astellas team up with Merck for a late-stage study to evaluate the enfortumab vedotin and Keytruda combo in patients with previously untreated metastatic urothelial cancer.
Biotech Tops in November: Best ETFs & Stocks http://www.zacks.com/stock/news/646838/biotech-tops-in-november-best-etfs-stocks?cid=CS-ZC-FT-etf_news_and_commentary-646838 Nov 29, 2019 - The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
5 New Drug Approvals the FDA Gave Top Priority https://www.fool.com/investing/2019/11/29/5-new-drug-approvals-the-fda-gave-top-priority.aspx?source=iedfolrf0000001 Nov 29, 2019 - Here's why the FDA recently approved five new drugs way ahead of schedule.
Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag http://www.zacks.com/stock/news/644810/incytes-nda-for-pemigatinib-gets-fdas-priority-review-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-644810 Nov 28, 2019 - The FDA accepts and grants priority review to Incyte's (INCY) new drug application for pemigatinib as a second-line treatment for patients with FGFR2 translocated cholangiocarcinoma.
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal http://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-638202 Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Genomics ETFs Surge on CRISPR's Gene Editing Progress http://www.zacks.com/stock/news/637553/genomics-etfs-surge-on-crisprs-gene-editing-progress?cid=CS-ZC-FT-etf_news_and_commentary-637553 Nov 25, 2019 - The release of encouraging data on the CRISPR/Cas9 gene-editing therapy CTX001 for two severe blood disorders puts emphasis on some genomic ETFs.

Pages: 123456...35

Page 1>